Mastodon

Ceftriaxone (Powder) Instructions for Use

ATC Code

J01DD04 (Ceftriaxone)

Active Substance

Ceftriaxone (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Third generation cephalosporin

Pharmacotherapeutic Group

Systemic antibacterial agents; other beta-lactam antibacterial agents; third-generation cephalosporins

Pharmacological Action

A broad-spectrum cephalosporin antibiotic of the third generation. It exerts a bactericidal effect by inhibiting the synthesis of the bacterial cell wall.

Ceftriaxone acetylates membrane-bound transpeptidases, thereby disrupting the cross-linking of peptidoglycans, which is necessary to ensure the strength and rigidity of the cell wall.

It is active against aerobic, anaerobic, gram-positive and gram-negative bacteria.

It is resistant to the action of beta-lactamases.

Pharmacokinetics

Plasma protein binding is 85-95%.

Ceftriaxone is widely distributed in body tissues and fluids. Therapeutic concentrations are achieved in the cerebrospinal fluid in meningitis. High concentrations are achieved in bile. It crosses the placental barrier and is excreted in breast milk in small amounts.

About 40-65% of ceftriaxone is excreted unchanged in the urine. The remainder is excreted in bile and feces.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to ceftriaxone, including peritonitis, sepsis, meningitis, cholangitis, gallbladder empyema, shigellosis, salmonella carriage, pneumonia, lung abscess, pleural empyema, pyelonephritis, infections of bones, joints, skin and soft tissues, genital organs, infected wounds and burns.

Prevention of postoperative infection.

ICD codes

ICD-10 code Indication
A01 Typhoid and paratyphoid
A02 Other salmonella infections
A03 Shigellosis
A40 Streptococcal sepsis
A41 Other sepsis
G00 Bacterial meningitis, not elsewhere classified
J15 Bacterial pneumonia, not elsewhere classified
J85 Abscess of lung and mediastinum
J86 Pyothorax (pleural empyema)
K65.0 Acute peritonitis (including abscess)
K81.0 Acute cholecystitis
K81.1 Chronic cholecystitis
K83.0 Cholangitis
L01 Impetigo
L02 Cutaneous abscess, furuncle and carbuncle
L03 Cellulitis
L08.0 Pyoderma
L08.8 Other specified local infections of skin and subcutaneous tissue
M00 Pyogenic arthritis
M86 Osteomyelitis
N10 Acute tubulointerstitial nephritis (acute pyelonephritis)
N11 Chronic tubulointerstitial nephritis (chronic pyelonephritis)
N30 Cystitis
N34 Urethritis and urethral syndrome
N41 Inflammatory diseases of prostate
N70 Salpingitis and oophoritis
N71 Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess)
N72 Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis)
N73.5 Unspecified female pelvic peritonitis
T79.3 Posttraumatic wound infection, not elsewhere classified
Z22.0 Carrier of typhoid fever
Z29.2 Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes)
ICD-11 code Indication
1A02 Intestinal infections due to Shigella
1A07.Z Typhoid fever, unspecified
1A08 Paratyphoid fever
1A09.Z Salmonella infection, unspecified
1B70.1 Streptococcal cellulitis of the skin
1B70.2 Staphylococcal cellulitis of the skin
1B70.Z Bacterial cellulitis or lymphangitis caused by unspecified bacterium
1B72.0 Bullous impetigo
1B72.1 Nonbullous impetigo
1B72.Z Impetigo, unspecified
1B75.0 Furuncle
1B75.1 Carbuncle
1B75.2 Furunculosis
1B75.3 Pyogenic skin abscess
1B7Y Other specified pyogenic bacterial infections of skin or subcutaneous tissue
1C44 Non-pyogenic bacterial infections of skin
1D01.0Z Bacterial meningitis, unspecified
1G40 Sepsis without septic shock
CA40.0Z Bacterial pneumonia, unspecified
CA43.Z Abscess of lung or mediastinum, unspecified
CA44 Pyothorax
DC12.0Z Acute cholecystitis, unspecified
DC12.1 Chronic cholecystitis
DC13 Cholangitis
DC50.0 Primary peritonitis
DC50.2 Peritoneal abscess
DC50.Z Peritonitis, unspecified
EA50.3 Staphylococcal scarlet fever
EB21 Pyoderma gangrenosum
FA1Z Infectious arthropathies, unspecified
FB84.Z Osteomyelitis or osteitis, unspecified
GA01.Z Inflammatory diseases of uterus, except cervix, unspecified
GA05.2 Unspecified pelvic peritonitis in women
GA07.Z Salpingitis and oophoritis, unspecified
GA91.Z Inflammatory and other diseases of prostate, unspecified
GB50 Acute tubulo-interstitial nephritis
GB51 Acute pyelonephritis
GB55.Z Chronic tubulo-interstitial nephritis, unspecified
GB5Z Renal tubulo-interstitial diseases, unspecified
GC00.Z Cystitis, unspecified
GC02.Z Urethritis and urethral syndrome, unspecified
NF0A.3 Posttraumatic wound infection, not elsewhere classified
QC05.Y Other specified prophylactic measures
QD00 Carriage of Salmonella typhi
1A0Z Bacterial intestinal infections, unspecified
XN0QE Salmonellae
GA0Z Inflammatory diseases of female genital tract, unspecified
XA5WW1 Cervix uteri

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Powder

Individual. Administered intramuscularly or intravenously at 1-2 g every 24 hours or 0.5-1 g every 12 hours. Depending on the etiology of the disease, it can be administered intramuscularly at a dose of 250 mg once. The daily dose for newborns is 20-50 mg/kg; for children aged 2 months to 12 years – 20-100 mg/kg; frequency of administration is once a day. The duration of the course is determined individually. In patients with impaired renal function, adjustment of the dosing regimen is required, taking into account the creatinine clearance values.

Maximum daily doses for adults – 4 g, for children – 2 g.

Adverse Reactions

From the digestive system: nausea, vomiting, diarrhea, transient increase in the activity of liver transaminases, cholestatic jaundice, hepatitis, pseudomembranous colitis.

Allergic reactions: skin rash, itching, eosinophilia; rarely – angioedema.

From the hematopoietic system: with prolonged use in high doses, changes in the peripheral blood picture are possible (leukopenia, neutropenia, thrombocytopenia, hemolytic anemia).

From the blood coagulation system: hypoprothrombinemia.

From the urinary system: interstitial nephritis.

Effects due to chemotherapeutic action: candidiasis.

Local reactions: phlebitis (with intravenous administration), pain at the injection site (with intramuscular administration).

Contraindications

Hypersensitivity to ceftriaxone and other cephalosporins.

Use in Pregnancy and Lactation

Adequate and strictly controlled studies on the safety of ceftriaxone during pregnancy have not been conducted.

The use of ceftriaxone during pregnancy and lactation is possible in cases where the intended therapeutic benefit for the mother outweighs the potential risk to the fetus.

Ceftriaxone is excreted in breast milk in low concentrations.

In experimental animal studies, no teratogenic or embryotoxic effects of ceftriaxone were found.

Use in Renal Impairment

In patients with impaired renal function, adjustment of the dosing regimen is required, taking into account the creatinine clearance values.

Use with caution in severe renal impairment.

Pediatric Use

In newborns with hyperbilirubinemia, especially premature infants, use is possible under strict medical supervision.

Special Precautions

In patients with hypersensitivity to penicillins, allergic reactions to cephalosporin antibiotics are possible.

Use with caution in severe renal impairment.

Ceftriaxone solutions should not be mixed or administered simultaneously with other antimicrobial drugs or solutions.

In newborns with hyperbilirubinemia, especially premature infants, use is possible under strict medical supervision.

Drug Interactions

Ceftriaxone, by suppressing the intestinal flora, hinders the synthesis of vitamin K. Therefore, with simultaneous use with drugs that reduce platelet aggregation (NSAIDs, salicylates, sulfinpyrazone), the risk of bleeding increases. For the same reason, with simultaneous use with anticoagulants, an enhancement of the anticoagulant effect is noted.

With simultaneous use with “loop” diuretics, the risk of nephrotoxic effects increases.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Fresenius Kabi Deutschland, GmbH (Germany)

Manufactured By

Labesfal-Laboratorios Almiro, S.A. (Portugal)

Dosage Form

Bottle Rx Icon Ceftriaxone Kabi Powder for solution for intravenous and intramuscular administration 1000 mg: fl. 1 or 10 pcs.

Dosage Form, Packaging, and Composition

Powder for solution for intravenous and intramuscular administration almost white or yellowish in color, crystalline.

1 vial
Ceftriaxone sodium sesquihydrate 1193 mg,
   Equivalent to ceftriaxone content 1000 mg

1000 mg – glass vials with a capacity of 15 ml (1) – cardboard packs.
1000 mg – glass vials with a capacity of 15 ml (10) – cardboard packs.

Marketing Authorization Holder

Fresenius Kabi Deutschland, GmbH (Germany)

Manufactured By

Labesfal-Laboratorios Almiro, S.A. (Portugal)

Dosage Form

Bottle Rx Icon Ceftriaxone Kabi Powder for solution for intravenous and intramuscular administration 500 mg: fl. 1 or 10 pcs.

Dosage Form, Packaging, and Composition

Powder for solution for intravenous and intramuscular administration almost white or yellowish in color, crystalline.

1 vial
Ceftriaxone sodium sesquihydrate 596.5 mg,
   Equivalent to ceftriaxone content 500 mg

500 mg – glass vials with a capacity of 15 ml (1) – cardboard packs.
500 mg – glass vials with a capacity of 15 ml (10) – cardboard packs.

Marketing Authorization Holder

Fresenius Kabi Deutschland, GmbH (Germany)

Manufactured By

Labesfal-Laboratorios Almiro, S.A. (Portugal)

Dosage Form

Bottle Rx Icon Ceftriaxone Kabi Powder for solution for infusions 2000 mg: vial 1 or 10 pcs.

Dosage Form, Packaging, and Composition

Powder for solution for infusions almost white or yellowish, crystalline.

1 vial
Ceftriaxone sodium sesquihydrate 2386 mg,
   Equivalent to ceftriaxone content 2000 mg

2000 mg – glass vials with a volume of 50 ml (1) – cardboard packs.
2000 mg – glass vials with a volume of 50 ml (10) – cardboard packs.

Marketing Authorization Holder

Fresenius Kabi Deutschland, GmbH (Germany)

Manufactured By

Labesfal-Laboratorios Almiro, S.A. (Portugal)

Dosage Form

Bottle Rx Icon Ceftriaxone Kabi Powder for solution for intravenous and intramuscular administration 2000 mg: vial 1 or 10 pcs.

Dosage Form, Packaging, and Composition

Powder for solution for intravenous and intramuscular administration almost white or yellowish in color, crystalline.

1 vial
Ceftriaxone sodium sesquihydrate 2386 mg,
   Equivalent to ceftriaxone content 2000 mg

2000 mg – glass vials with a capacity of 15 ml (1) – cardboard packs.
2000 mg – glass vials with a capacity of 15 ml (10) – cardboard packs.

Marketing Authorization Holder

Dominanta-Service, JSC (Russia)

Manufactured By

Fujian Fukang Pharmaceutical, Co. Ltd. (China)

Dosage Form

Bottle Rx Icon Ceftriaxone Danhson Powder for solution for intravenous and intramuscular administration 1 g: vial 1 or 10 pcs.

Dosage Form, Packaging, and Composition

Powder for solution for intravenous and intramuscular administration white or white with a yellowish tint.

1 vial
Ceftriaxone (in the form of ceftriaxone sodium sesquihydrate) 1 g

1 g – glass vials with a capacity of 15 ml (1) – cardboard packs.
1 g – glass vials with a capacity of 15 ml (10) – cardboard packs.

Marketing Authorization Holder

Dominanta-Service, JSC (Russia)

Manufactured By

Mekophar Chemical-Pharmaceutical, Joint Stock Company (Vietnam)

Dosage Form

Bottle Rx Icon Ceftriaxone DS Powder for solution for intravenous and intramuscular administration 1 g: vial. 1 pc.

Dosage Form, Packaging, and Composition

Powder for solution for intravenous and intramuscular administration 1 vial
Ceftriaxone (in the form of sodium salt) 1 g

1 g – vials (1) – cardboard packs.

Marketing Authorization Holder

Elfa SPC, JSC (Russia)

Manufactured By

Elfa Laboratories (India)

Dosage Form

Bottle Rx Icon Ceftriaxone Elfa® Powder for solution for intravenous and intramuscular administration 1 g: vial. 1 pc.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intravenous and intramuscular administration 1 vial
Ceftriaxone (as sodium salt) 1 g

10 ml vials (1) – cardboard packs.

Marketing Authorization Holder

Protech Biosystems, Pvt. Ltd. (India)

Dosage Form

Bottle Rx Icon Ceftriaxone Protech Powder for solution for intravenous and intramuscular administration 1 g: vial. 1 pc.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intravenous and intramuscular administration 1 vial
Ceftriaxone (as sodium salt) 1 g

1 g – vials (1) – cardboard packs.

Marketing Authorization Holder

Biokhimik, JSC (Russia)

Dosage Form

Bottle Rx Icon Ceftriaxone sodium salt Powder for preparation of injection solution 250 mg: fl. 50 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of injection solution from white to yellowish color.

1 vial
Ceftriaxone (as sodium salt) 250 mg

250 mg – 10 ml vials (50) – cardboard boxes.

Marketing Authorization Holder

Biokhimik, JSC (Russia)

Dosage Form

Bottle Rx Icon Ceftriaxone sodium salt Powder for preparation of injection solution 500 mg: fl. 50 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of injection solution from white to yellowish color.

1 vial
Ceftriaxone (as sodium salt) 500 mg

500 mg – 10 ml vials (50) – cardboard boxes.

Marketing Authorization Holder

Biokhimik, JSC (Russia)

Dosage Form

Bottle Rx Icon Ceftriaxone sodium salt Powder for preparation of injection solution 1 g: fl. 50 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of injection solution from white to yellowish color.

1 vial
Ceftriaxone (as sodium salt) 1 g

1 g – 10 ml vials (50) – cardboard boxes.

Marketing Authorization Holder

Biokhimik, JSC (Russia)

Dosage Form

Bottle Rx Icon Ceftriaxone sodium salt Powder for preparation of injection solution 2 g: fl. 50 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of injection solution from white to yellowish color.

1 vial
Ceftriaxone (as sodium salt) 2 g

2 g – 10 ml vials (50) – cardboard boxes.

Marketing Authorization Holder

Binnopharm Group LLC (Russia)

Manufactured By

Sintez PJSC (Russia)

Dosage Form

Bottle Rx Icon Ceftriaxone-AKOS Powder for solution for intravenous and intramuscular administration 0.25 g: vial 1 or 10 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intravenous and intramuscular administration white or white with a yellowish tint.

1 vial
Ceftriaxone (as ceftriaxone sodium) 0.25 g

0.25 g – glass vials (1) – cardboard packs.
0.25 g – glass vials (10) – cardboard packs.

Marketing Authorization Holder

Sintez PJSC (Russia)

Dosage Forms

Bottle Rx Icon Ceftriaxone-Akos Powder for solution for intravenous and intramuscular administration 0.5 g: vial 1 or 10 pcs.
Powder for solution for intravenous and intramuscular administration 1 g: vial 1 or 10 pcs.
Powder for solution for intravenous and intramuscular administration 2 g: vial. 1 or 10 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intravenous and intramuscular administration white or white with a yellowish tint.

1 vial
Ceftriaxone sodium 0.535 g
   Equivalent to ceftriaxone content 0.5 g

0.5 g – glass vials (1) with a capacity of 10 ml or 20 ml – cardboard packs.
0.5 g – glass vials (10) with a capacity of 10 ml or 20 ml – cardboard packs.

Powder for preparation of solution for intravenous and intramuscular administration white or white with a yellowish tint.

1 vial
Ceftriaxone sodium 1.071 g
   Equivalent to ceftriaxone content 1 g

1 g – glass vials (1) with a capacity of 10 ml or 20 ml – cardboard packs.
1 g – glass vials (10) with a capacity of 10 ml or 20 ml – cardboard packs.

Powder for preparation of solution for intravenous and intramuscular administration white or white with a yellowish tint.

1 vial
Ceftriaxone sodium 2.142 g
   Equivalent to ceftriaxone content 2 g

2 g – glass vials (1) with a capacity of 10 ml or 20 ml – cardboard packs.
2 g – glass vials (10) with a capacity of 10 ml or 20 ml – cardboard packs.

Marketing Authorization Holder

Alpa Expoim, LLC (Russia)

Manufactured By

Cooper Pharma (India)

Dosage Form

Bottle Rx Icon Ceftriaxone-Alpa Powder for solution for intravenous and intramuscular administration 1 g: vial. 1 pc.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intravenous and intramuscular administration 1 vial
Ceftriaxone (as sodium salt) 1 g

1 g – vials (1) – cardboard packs.

Marketing Authorization Holder

Darnitsa Pharmaceutical Firm, PJSC (Ukraine)

Dosage Form

Bottle Rx Icon Ceftriaxone-Darnitsa Powder for solution for intravenous and intramuscular administration 1 g: vial. 1 pc.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intramuscular administration 1 vial
Ceftriaxone (as sodium salt) 1 g

Vials (1) – cardboard packs.

Marketing Authorization Holder

Darnitsa Pharmaceutical Firm, PJSC (Ukraine)

Dosage Form

Bottle Rx Icon Ceftriaxone-Darnitsa Powder for solution for intravenous and intramuscular administration 500 mg: fl. 1 pc.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intramuscular administration 1 vial
Ceftriaxone (as sodium salt) 500 mg

Vials (1) – cardboard packs.

Marketing Authorization Holder

Jodas Expoim, LLC (Russia)

Manufactured By

Jodas Expoim, Pvt. Ltd. (India)

Or

Interpharma, LLC (Russia)

Dosage Form

Bottle Rx Icon Ceftriaxone-Jodas Powder for solution for intravenous and intramuscular administration 1 g: vial. 1, 10, 20, 25, 48, 50, or 100 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intravenous and intramuscular administration 1 vial
Ceftriaxone (as sodium salt) 1 g

Vials (1) – cardboard boxes.
Vials (10) – cardboard boxes.
Vials (20) – cardboard boxes.
Vials (25) – cardboard boxes.
Vials (48) – cardboard boxes.
Vials (50) – cardboard boxes.
Vials (100) – cardboard boxes.

Marketing Authorization Holder

Alvils, LLC (Russia)

Dosage Form

Bottle Rx Icon Ceftriaxone-KMP Powder for solution for intravenous and intramuscular administration 500 mg: vial 1, 10 or 40 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intravenous and intramuscular administration 1 vial
Ceftriaxone (as sodium salt) 500 mg

500 mg – vials (1) – cardboard packs.
500 mg – vials (10) – contour cell packs (1) – cardboard packs.
500 mg – vials (40) – cardboard packs.

Marketing Authorization Holder

Alvils, LLC (Russia)

Dosage Form

Bottle Rx Icon Ceftriaxone-KMP Powder for solution for intravenous and intramuscular administration 1 g: vial 1, 10 or 40 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intravenous and intramuscular administration 1 vial
Ceftriaxone (as sodium salt) 1 g

1 g – vials (1) – cardboard packs.
1 g – vials (10) – contour cell packs (1) – cardboard packs.
1 g – vials (40) – cardboard packs.

Marketing Authorization Holder

Protek-SVM LLC (Russia)

Manufactured By

Interpharma, LLC (Russia)

Or

Ruzpharma, LLC (Russia)

Dosage Form

Bottle Rx Icon Ceftriaxone-LEKSVM® Powder for solution for intravenous and intramuscular administration 1 g: vial. 1 pc.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intravenous and intramuscular administration white or white with a yellowish tint.

1 vial
Ceftriaxone sodium sesquihydrate 1193 mg,
   Calculated as Ceftriaxone 1000 mg

1 g – glass vials (1) – cardboard packs.

Marketing Authorization Holder

Protek-SVM LLC (Russia)

Manufactured By

Redkinsky Pilot Plant, PJSC (Russia)

Dosage Form

Bottle Rx Icon Ceftriaxone-LEKSVM Powder for solution for intravenous and intramuscular administration 0.5 g: vial 1, 10, or 50 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intravenous and intramuscular administration white or white with a yellowish tint.

1 vial
Ceftriaxone (as sodium salt) 500 mg

0.5 g – glass vials (1) – cardboard packs.
0.5 g – glass vials (10) – cardboard boxes.
0.5 g – glass vials (50) – cardboard boxes (for hospitals).

Marketing Authorization Holder

Protek-SVM LLC (Russia)

Manufactured By

Redkinsky Pilot Plant, PJSC (Russia)

Labeled By

PROTEK-SVM, LLC (Russia)

Dosage Form

Bottle Rx Icon Ceftriaxone-LEKSVM Powder for solution for intravenous and intramuscular administration 1 g: vial. 1, 10, or 50 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of solution for intravenous and intramuscular administration white or white with a yellowish tint.

1 vial
Ceftriaxone (as sodium salt) 1000 mg

1 g – glass vials (1) – cardboard packs.
1 g – glass vials (10) – cardboard boxes.
1 g – glass vials (50) – cardboard boxes (for hospitals).

Marketing Authorization Holder

Promed Exports, Pvt. Ltd. (India)

Dosage Form

Bottle Rx Icon Ceftriaxone-Promed Powder for solution for intravenous and intramuscular administration 1 g: vial. 1 or 50 pcs.

Dosage Form, Packaging, and Composition

Powder for solution for intravenous and intramuscular administration crystalline, white or white with a yellowish tint.

1 vial
Ceftriaxone (as sodium salt) 1 g

1 g – Colorless glass vials with a capacity of 10 ml (1) – cardboard packs.
1 g – Colorless glass vials with a capacity of 10 ml (50) – cardboard boxes.

Marketing Authorization Holder

Vial, LLC (Russia)

Manufactured By

NORTH CHINA PHARMACEUTICAL CORPORATION (China)

Dosage Form

Bottle Rx Icon Ceftriaxone-Vial Powder for solution for intravenous and intramuscular administration 1 g: vial. 1 pc.

Dosage Form, Packaging, and Composition

Powder for solution for intravenous and intramuscular administration 1 vial
Ceftriaxone (as sodium salt) 1 g

1 g – vials (1) – cardboard packs.

Marketing Authorization Holder

Vial, LLC (Russia)

Manufactured By

NORTH CHINA PHARMACEUTICAL CORPORATION (China)

Dosage Form

Bottle Rx Icon Ceftriaxone-Vial Powder for solution for intravenous and intramuscular administration 1 g: fl. 1 pc. (packaged by Ozon LLC)

Dosage Form, Packaging, and Composition

Powder for solution for intravenous and intramuscular administration 1 vial
Ceftriaxone (as sodium salt) 1 g

Vials (1) – cardboard packs.

Table of Contents

→ TABLE OF CONTENTS